<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03136302</url>
  </required_header>
  <id_info>
    <org_study_id>DBS2017</org_study_id>
    <nct_id>NCT03136302</nct_id>
  </id_info>
  <brief_title>Correlation of Tractography and Motor Evoked Potentials in Deep Brain Stimulation</brief_title>
  <official_title>Correlation of Tractography and Motor Evoked Potentials in Deep Brain Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lutz Weise</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nova Scotia Health Authority</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal is to establish another anatomical referencing system in order to achieve an even
      higher accuracy when implanting stimulation electrodes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main goal is to find out what are the optimal distances to these reference fiber tracts
      when stimulating and to find the optimal target. This has to be evaluated for each target,
      such as globus pallidus (Gpi), subthalamic nucleus (STN) and ventral intermediate nucleus of
      the thalamus (VIM) separately. This is of special importance as the investigators can
      demonstrate the internal capsule, which is often a generator of stimulation-induced side
      effects: tetanic muscle contractions, dysarthria and gaze deviations.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>distance between stimulation electrode and motor fibers in mm</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Distances between the stimulation electrode and motor fibers as depicted on fiber tracking in millimeters in correlation to the threshold current for eliciting clinical side effects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraoperative intensity of stimulation in milliampere (mA)</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Intraoperative intensity of stimulation in milliamp, which elicits an activation of contralateral muscle groups (musculus interosseus dorsalis and the musculus tibialis anterior)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stimulation thresholds in milliampere (mA)</measure>
    <time_frame>Intraoperative</time_frame>
    <description>Threshold of intraoperative stimulation intensity in milliamp, which elicits capsular side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in disease score units on the UPDRS rating scale</measure>
    <time_frame>twelve months</time_frame>
    <description>Assessment of therapeutic effects using Unified Parkinson disease rating scale (UPDRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in disease score units on the FTRS rating scale</measure>
    <time_frame>twelve months</time_frame>
    <description>Assessment of therapeutic effects using, Fahn-Tremor Rating Scale (FTRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in disease score units on the BFMDRS rating scale</measure>
    <time_frame>twelve months</time_frame>
    <description>Assessment of therapeutic effects using Burke-Fahn-Marsden dystonia rating scale (BFMDRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in disease score units on the TWSTR rating scale</measure>
    <time_frame>twelve months</time_frame>
    <description>Assessment of therapeutic effects using Toronto Western Spasmodic torticollis rating scale (TWSTR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in disease score units on the PDQ-39 rating scale</measure>
    <time_frame>twelve months</time_frame>
    <description>Assessment of therapeutic effects using Parkinsons Disease QuestionnairePDQ-39</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Improving Accuracy of Implanting Stimulation Electrodes</condition>
  <arm_group>
    <arm_group_label>Subthalamic Nucleus (STN)</arm_group_label>
    <description>Patients with Parkinson's disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Globus Pallidus (Gpi)</arm_group_label>
    <description>Patients with Dystonia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ventral intermediate nucleus of the thalamus (VIM)</arm_group_label>
    <description>Patients with Tremor</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Deep Brain Stimulation</intervention_name>
    <description>Deep Brain Stimulation</description>
    <arm_group_label>Subthalamic Nucleus (STN)</arm_group_label>
    <arm_group_label>Globus Pallidus (Gpi)</arm_group_label>
    <arm_group_label>Ventral intermediate nucleus of the thalamus (VIM)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who qualify for deep brain stimulation on the basis of a movement disorder and
        chronic pain
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient qualifying for deep brain stimulation on the basis of a movement disorder
             (Parkinson's Disease, tremor, dystonia) or chronic pain disease.

          -  Informed consent

        Exclusion Criteria:

          -  Lack of consent

          -  Electrical or other devices that preclude the performance of an MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lutz Weise, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dalhousie University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lutz Weise, MD</last_name>
    <phone>902-473-6850</phone>
    <email>lutz.weise@nshealth.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Queen Elizabeth Health Science Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lutz Weise, MD</last_name>
      <phone>902-473-6850</phone>
      <email>lutz.weise@nshealth.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2017</study_first_submitted>
  <study_first_submitted_qc>April 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2017</study_first_posted>
  <last_update_submitted>December 14, 2017</last_update_submitted>
  <last_update_submitted_qc>December 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nova Scotia Health Authority</investigator_affiliation>
    <investigator_full_name>Lutz Weise</investigator_full_name>
    <investigator_title>Neurosurgery, Head of Neuromodulation, Associate Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

